🇺🇸 FDA

Company profile · Sponsor

Cellectar

Cellectar Biosciences

CLRB · NYSE pharma FLORHAM PARK, NJ, USA
Pipeline
17
Drugs
0
Patents
7

Quick answer

Cellectar (CLRB) is a pharma company. headquartered in FLORHAM PARK, NJ, USA. listed on NYSE. NovaPharmaNews links 17 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker CLRB
Exchange NYSE
Company type pharma
Headquarters FLORHAM PARK, NJ, USA
SEC CIK 0001279704

Pipeline (17)

Search pipeline →

  1. Paclitaxel

    Cellectar

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  2. I-124-CLR1404

    Cellectar

    Glioblastoma

    phase 2 small molecule terminated

    1 trial

  3. I-131-CLR1404 Injection

    Cellectar

    Glioma

    phase 2 small molecule terminated

    1 trial

  4. Iopofosine I 131 single dose

    Cellectar

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  5. NOV-002

    Cellectar

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  6. NOV-002

    Cellectar

    Leukemia

    phase 2 small molecule terminated

    1 trial

  7. NOV-205

    Cellectar

    Hepatitis C

    phase 2 small molecule completed

    2 trials

  8. POTASSIUM IODIDE

    Cellectar

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  9. CLR 131

    Cellectar

    Head and Neck Cancer

    phase 1 small molecule completed

    1 trial

  10. CLR 131

    Cellectar

    High-Grade Glioma

    phase 1 small molecule active

    1 trial

  11. CLR 131

    Cellectar

    Pediatric Solid Tumor

    phase 1 small molecule active

    1 trial

  12. I-131-CLR1404

    Cellectar

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. I-131-CLR1404

    Cellectar

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  14. I-131-CLR1404

    Cellectar

    Cancer

    phase 1 small molecule completed

    1 trial

  15. I124-NM404

    Cellectar

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  16. Iopofosine I 131

    Cellectar

    Breast Cancer

    phase 1 small molecule active

    1 trial

  17. RNL-Vascostem®

    Cellectar

    Buerger's Disease

    mab completed

    1 trial

Patents (7)

Search patents →

  1. US 11439709

    Phospholipid ether analogs as cancer-targeting drug vehicles

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9925269

    Phospholipid ether analogs as cancer-targeting drug vehicles

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9616140

    Fluorescent phospholipid ether compounds, compositions, and methods of use

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9579406

    Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9550002

    Phospholipid analogs as diapeutic agents and methods thereof

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9480754

    Phospholipid ether analogs as cancer-targeting drug vehicles

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9345718

    Phospholipid ether analogs as cancer-targeting drug vehicles

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Cellectar?

Cellectar (CLRB) is a pharma company. headquartered in FLORHAM PARK, NJ, USA. listed on NYSE. NovaPharmaNews links 17 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does Cellectar sponsor?

We track 17 ClinicalTrials.gov-linked programs for Cellectar, including Paclitaxel and 16 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cellectar company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.